DNA Sequencing Industry Report by Regional Category Spend, Price Analysis, Key Demand and Price Indicators, and Best Buying Practices

The global DNA Sequencing market reached a value of about USD 9.1 billion in 2021. The industry is projected to grow at a CAGR of around 22% in the forecast period of 2022-2027 to reach a value of about USD 30 billion by 2027.

The global DNA Sequencing industry report gives a comprehensive analysis of the industry, including key segments, trends, drivers, restraints, the competitive landscape, and other essential market aspects. The wide range of technology applications is driving the market's development. North America is the highest category spender by region, driving the demand for the DNA Sequencing industry.

Industry Definition and Segmentation

Sequencing DNA entails establishing the order of the four chemical building units that make up the DNA molecule (adenine, thymine, cytosine, and guanine, or "bases"). Rapid DNA sequencing devices have substantially developed biological and medical study and breakthroughs. The sequence informs scientists about the genetic information contained by a particular DNA segment.

The DNA Sequencing industry report comprises segments by end-users (Academics & Research Institutes, Pharma & Biotech and Hospitals & Clinics), application (Clinical and Non-Clinical), and region (North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America).

North America Region is Driving the Growth of the Industry

North America holds the largest share in the industry due to the increased financing and support efforts by government and non-government groups, particularly in the United States. The fundamental driving forces for DNA sequencing in the nation are the rising usage of modern technology and favourable government backing and legislation. Furthermore, the market is expanding due to the ongoing technical breakthroughs by significant companies, effective R&D expenditure, and the presence of technologically sophisticated healthcare infrastructure.

The market is being driven by DNA sequencing in Diagnostics, customised medicine, biomarkers, forensics, reproductive health, and other applications. It has simplified nucleotide analysis and has mostly superseded traditional genomics technologies such as microarray, genotyping, and others furthering its growth. In addition, the employment of technology in clinical research for the development of cancer diagnoses and therapies is likely to provide new opportunities. The next-generation sequencing (NGS) technology has proved its ability to identify and characterise clinically relevant genetic variations across several genes at an unprecedented speed in a single test, demonstrating its capability as a high-throughput and cheap technique. As a result, it is gaining traction in the industry. The technology's properties, such as speed, affordability, accuracy, efficient replacement of conventional technologies, and drug discovery applications requiring NGS technology, drive the market demand.

Best Procurement Practices

The global DNA Sequencing industry report by Procurement Resource gives an in-depth analysis of the best buying practices followed by major global DNA Sequencing regions, such as engagement models, contract terms, and buyer and supplier negotiation levers, among others.

Category Management Studies

The process involves various methods; the Sanger method is a traditional DNA sequencing method that prevents the addition of another nucleotide by using fluorescent ddNTPs (dideoxynucleotides, N = A, T, G, or C). Secondly, massively parallel sequencing, also known as next-generation sequencing, may establish the order of millions of pieces simultaneously. NGS is a type of short-read sequencing that involves building a small fragment library, deep sequencing, raw data pre-processing, DNA sequence alignment, assembly, annotation, and downstream analysis. Also, Third-generation sequencing or long-read sequencing incorporating PacBio SMRT sequencing and Oxford nanopore sequencing can look at billions of DNA and RNA templates at once and find varied methylations without bias. Long-read techniques can detect more variants, including those that short-read sequencing alone cannot detect.

Technological Breakthroughs, Further Augmenting the DNA Sequencing Market

The industry is witnessing growth due to the various technological developments in medicine, resulting in the creation of customised treatment. Next-generation sequencing has a wide range of applications in personalised medicine. Furthermore, promising potential in biomarkers, cancer, diagnostics, personalised medicine, forensics, and reproductive health is expected to fuel worldwide growth. Moreover, Platforms like Illumina/ Solexa, ABI/ SOLiD, 454/Roche, and Helicos have opened up new possibilities for high-throughput functional genomics research. Furthermore, biologists and informatics professionals have been concentrating on creating better genomes, which have been made feasible by newer sequencing technology, unique ways for finding sequences on chromosomes, and enhanced DNA sequencing software. Other market expansion factors include increased partnerships, collaborations, rise in DNA sequencing technological developments, expanded use in clinical diagnostics and drug discovery, and growing R&D spending.

The regional markets for the industry can be divided into North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Key Industry Players Mentioned in the DNA Sequencing Industry Report

• Charles River Laboratories International, Inc.
• Labcorp Drug Development
• Eurofins GSC Lux SARL
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.

Market Landscape

The worldwide DNA sequencing business is fiercely competitive, with just a few large competitors remaining. These players are attempting to meet expanding customer demand by investing significantly in manufacturing, distribution, and comprehensive quality control to expand their product lines.

Key Initiatives by Companies

• Sysmex Corporation introduced the XR-Series automated haematology analyser, its next-generation flagship model in the haematology area, in March 2021, and the XQ-Series automated haematology analyser, a small 3-part WBC differential model.
• Face2Gene LABS was launched in June 2019 by PerkinElmer and FDNA, an artificial intelligence startup, to deliver genomic services in conjunction with Next-Generation Phenotyping (NGP) technologies for more accurate and efficient diagnosis. Perkin Elmer's dedication to diagnosing patients with genetic and uncommon illnesses was demonstrated by this project, which provided high-quality genomic testing alternatives and efficiency.